JG
TCRT icon

Jefferies Group’s Alaunos Therapeutics TCRT Stock Holding History

Jefferies Group’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-130
Closed -$92K – 2650
2019
Q4 		$92K Buy
+130
New +$89.5K ﹤0.01% 2395
2019
Q1 		– Sell
-771
Closed -$216K – 2622
2018
Q4 		$216K Buy
771
+125
+19% +$49.4K ﹤0.01% 1797
2018
Q3 		$310K Buy
646
+324
+101% +$139K ﹤0.01% 1858
2018
Q2 		$146K Buy
+322
New +$204K ﹤0.01% 2086
2015
Q3 		– Sell
-2
Closed -$3K – 2988
2015
Q2 		$3K Buy
+2
New +$3.1K ﹤0.01% 3104

Other funds holding TCRT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MVP
Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Jefferies Group's TCRT Position: Q1 2020 in Review

Jefferies Group sold out of Alaunos Therapeutics (TCRT) in Q1 2020, closing a stake of 130 shares — an estimated $92K sold.

Jefferies Group first reported a position in TCRT in Q2 2015 and held it in 5 quarters. The position peaked at $310K in Q3 2018. 146 funds tracked by Wall St. Rank hold TCRT as of Q1 2020.

  • Jefferies Group reported no remaining Alaunos Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Jefferies Group sold 130 Alaunos Therapeutics shares in Q1 2020, an estimated $92K.
  • Jefferies Group first reported a position in Alaunos Therapeutics in Q2 2015 and held it in 5 quarters.
  • Jefferies Group's Alaunos Therapeutics position peaked at $310K in Q3 2018.
  • 146 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q1 2020.

Based on Jefferies Group's 13F filing for Q1 2020, filed 15 May 2020.